{"transactions":[{"id":743394,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:46:23.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266129","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266129/ownership.xml","form_type":"4"}},{"id":794171,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-04T22:05:45.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":210526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":67031},"source":{"system":"sec-edgar","filing":"0001193125-26-204465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204465/ownership.xml","form_type":"4"}},{"id":794170,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T22:05:45.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":991192,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":991192,"derivative":{"exercise_price":18,"exercise_date":"2026-04-30","expiration_date":"2036-04-29","underlying":"Common Stock","underlying_shares":991192},"source":{"system":"sec-edgar","filing":"0001193125-26-204465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204465/ownership.xml","form_type":"4"}},{"id":794169,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T22:05:45.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":12258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":12258,"derivative":{"exercise_price":18,"expiration_date":"2036-04-29","underlying":"Common Stock","underlying_shares":12258},"source":{"system":"sec-edgar","filing":"0001193125-26-204465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204465/ownership.xml","form_type":"4"}},{"id":794168,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:05:45.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":67031,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."}],"balance_after":863031,"source":{"system":"sec-edgar","filing":"0001193125-26-204465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204465/ownership.xml","form_type":"4"}},{"id":1040689,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-15T20:05:04.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":13382,"price":24.9712,"value":334164.5984,"ownership":{"direct":false,"nature":"By Paul Capital Strategy III Fund LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $24.90 to $25.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Paul Capital Strategy III Fund LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any."}],"balance_after":41666,"source":{"system":"sec-edgar","filing":"0001193125-25-203537","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525203537/ownership.xml","form_type":"4"}},{"id":1040688,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-15T20:05:04.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":28284,"price":24.4996,"value":692946.6864,"ownership":{"direct":false,"nature":"By Paul Capital Strategy III Fund LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $23.90 to $24.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Paul Capital Strategy III Fund LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any."}],"balance_after":28284,"source":{"system":"sec-edgar","filing":"0001193125-25-203537","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525203537/ownership.xml","form_type":"4"}},{"id":1106590,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T20:15:08.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":21850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":21850,"derivative":{"exercise_price":10.95,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":21850},"source":{"system":"sec-edgar","filing":"0000950170-25-087898","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025087898/ownership.xml","form_type":"4"}},{"id":1572163,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22800,"price":142.74,"value":3254472.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":0,"derivative":{"exercise_price":187.26,"expiration_date":"2023-02-08","underlying":"Common Stock","underlying_shares":22800},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572162,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":146900,"price":218.03,"value":32028607.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":0,"derivative":{"exercise_price":111.97,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":146900},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572161,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":161850,"price":198.36,"value":32104566.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":0,"derivative":{"exercise_price":131.64,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":161850},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572160,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135992,"price":230.28,"value":31316237.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":99.72,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":135992},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572159,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":71121,"price":309.98,"value":22046087.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":20.02,"expiration_date":"2019-06-27","underlying":"Common Stock","underlying_shares":71121},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572158,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":616703,"price":314,"value":193644742.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2019-06-26","underlying":"Common Stock","underlying_shares":616703},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572157,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15205,"price":320.8,"value":4877764.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.2,"expiration_date":"2029-04-07","underlying":"Common Stock","underlying_shares":15205},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572156,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":87494,"price":320.8,"value":28068075.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-28","underlying":"Common Stock","underlying_shares":87494},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572155,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":449463,"price":320.8,"value":144187730.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":449463},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572154,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":757045,"price":322.73,"value":244321132.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.27,"expiration_date":"2028-08-08","underlying":"Common Stock","underlying_shares":757045},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572153,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":136094,"price":322.96,"value":43952918.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.04,"expiration_date":"2028-04-29","underlying":"Common Stock","underlying_shares":136094},"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572152,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35877,"price":330,"value":11839410.0,"ownership":{"direct":false,"nature":"Jann E. Paul GRAT III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572151,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30304,"price":330,"value":10000320.0,"ownership":{"direct":false,"nature":"Steven M. Paul Family 2024 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572150,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33882,"price":330,"value":11181060.0,"ownership":{"direct":false,"nature":"The Steven M Paul Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572149,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"price":330,"value":3300000.0,"ownership":{"direct":false,"nature":"Jann E Paul Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572148,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30304,"price":330,"value":10000320.0,"ownership":{"direct":false,"nature":"Steve M. Paul Family 2021 Delaware Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572147,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8550,"price":330,"value":2821500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1572146,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2046,"price":330,"value":675180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13."}],"balance_after":8550,"source":{"system":"sec-edgar","filing":"0001140361-24-013933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000114036124013933/form4.xml","form_type":"4"}},{"id":1602668,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:34:31.000Z","date":"2024-03-04","kind":"gift","planned":false,"acquired":true,"shares":30304,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Steven M. Paul Family 2024 Trust"},"balance_after":30304,"source":{"system":"sec-edgar","filing":"0000950170-24-024999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024024999/ownership.xml","form_type":"4"}},{"id":1602667,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:34:31.000Z","date":"2024-03-04","kind":"gift","planned":false,"acquired":false,"shares":30304,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Steven M Paul Revocable Trust"},"balance_after":2364,"source":{"system":"sec-edgar","filing":"0000950170-24-024999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024024999/ownership.xml","form_type":"4"}},{"id":1602666,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:34:31.000Z","date":"2024-03-01","kind":"gift","planned":false,"acquired":true,"shares":30304,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Steven M Paul Revocable Trust"},"balance_after":32668,"source":{"system":"sec-edgar","filing":"0000950170-24-024999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024024999/ownership.xml","form_type":"4"}},{"id":1602665,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:34:31.000Z","date":"2024-03-01","kind":"gift","planned":false,"acquired":false,"shares":30304,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Jann E Paul Revocable Trust"},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000950170-24-024999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024024999/ownership.xml","form_type":"4"}},{"id":1602664,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:34:31.000Z","date":"2024-03-01","kind":"gift","planned":false,"acquired":true,"shares":30304,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Steve M. Paul Family 2021 Delaware Trust"},"balance_after":30304,"source":{"system":"sec-edgar","filing":"0000950170-24-024999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024024999/ownership.xml","form_type":"4"}},{"id":1602663,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:34:31.000Z","date":"2024-03-01","kind":"gift","planned":false,"acquired":false,"shares":30304,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Jann E Paul Revocable Trust"},"balance_after":40304,"source":{"system":"sec-edgar","filing":"0000950170-24-024999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024024999/ownership.xml","form_type":"4"}},{"id":1602662,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:34:31.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":true,"shares":47378,"price":315.18,"value":14932598.04,"ownership":{"direct":false,"nature":"Jann E Paul Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 29, 2024, the Jann E Paul Revocable Trust, a family trust of which the reporting person is the trustee (the \"Revocable Trust\"), withdrew 47,378 shares of common stock from the Jann E. Paul GRAT III, a grantor retained annuity trust established for the benefit of the reporting person (the \"GRAT\"), in exchange for cash. The withdrawal of shares from the the GRAT resulted in a decrease in the number of shares the reporting person beneficially owns indirectly through the GRAT and a corresponding increase in the number of shares the reporting person beneficially owns indirectly through the Revocable Trust. The reporting person believes that this withdrawal of shares from the GRAT constitutes a change in form of beneficial ownership of the shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934, as amended."}],"balance_after":70608,"source":{"system":"sec-edgar","filing":"0000950170-24-024999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024024999/ownership.xml","form_type":"4"}},{"id":1618987,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-02-26T23:15:14.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":false,"shares":4008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 14, 2020, with additional vesting as to 6.25% of the shares underlying the option award on each three month anniversary thereafter."}],"balance_after":135992,"derivative":{"exercise_price":99.72,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":4008},"source":{"system":"sec-edgar","filing":"0000950170-24-020397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024020397/ownership.xml","form_type":"4"}},{"id":1618986,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-02-26T23:15:14.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":false,"shares":27510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vested as to 1/30th of the shares underlying the option award on each one month anniversary of the vesting commencement date of June 15, 2018, except that 274,594 shares vested upon the closing of our Series B financing in March 2019, and 98,069 shares vested upon the closing of our initial public offering."}],"balance_after":757045,"derivative":{"exercise_price":7.27,"expiration_date":"2028-08-08","underlying":"Common Stock","underlying_shares":27510},"source":{"system":"sec-edgar","filing":"0000950170-24-020397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024020397/ownership.xml","form_type":"4"}},{"id":1618985,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-26T23:15:14.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":true,"shares":4008,"price":99.72,"value":399677.76,"ownership":{"direct":true},"balance_after":42114,"source":{"system":"sec-edgar","filing":"0000950170-24-020397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024020397/ownership.xml","form_type":"4"}},{"id":1618984,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-26T23:15:14.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":true,"shares":27510,"price":7.27,"value":199997.7,"ownership":{"direct":true},"balance_after":38106,"source":{"system":"sec-edgar","filing":"0000950170-24-020397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024020397/ownership.xml","form_type":"4"}},{"id":1648976,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:13:11.000Z","date":"2024-02-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":804,"price":317.14,"value":254980.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the partial vesting of restricted stock units previously granted to the Reporting Person on February 9, 2023."}],"balance_after":10596,"source":{"system":"sec-edgar","filing":"0000950170-24-013963","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000095017024013963/ownership.xml","form_type":"4"}},{"id":1687386,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-01-04T21:07:48.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":3971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date."}],"balance_after":3971,"derivative":{"exercise_price":21.67,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":3971},"source":{"system":"sec-edgar","filing":"0001562180-24-000225","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218024000225/primarydocument.xml","form_type":"4"}},{"id":1851798,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T20:06:03.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 15, 2024 or the day immediately prior to the 2024 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":56.1,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-23-005261","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218023005261/primarydocument.xml","form_type":"4"}},{"id":2019612,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and President of R&D"}}],"security":"Option (Right to Buy)","published_at":"2023-02-13T21:15:43.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":22800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest on February 9, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":22800,"derivative":{"exercise_price":187.26,"expiration_date":"2023-02-08","underlying":"Common Stock","underlying_shares":22800},"source":{"system":"sec-edgar","filing":"0000899243-23-004747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924323004747/doc4.xml","form_type":"4"}},{"id":2019611,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and President of R&D"}}],"security":"Common Stock","published_at":"2023-02-13T21:15:43.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":11400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 9, 2024, subject to continued service through such dates."}],"balance_after":11400,"source":{"system":"sec-edgar","filing":"0000899243-23-004747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924323004747/doc4.xml","form_type":"4"}},{"id":2019610,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and President of R&D"}}],"security":"Common Stock","published_at":"2023-02-13T21:15:43.000Z","date":"2022-05-31","kind":"gift","acquired":true,"shares":106485,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Spouse (Jann E. Paul GRAT III)"},"balance_after":106485,"source":{"system":"sec-edgar","filing":"0000899243-23-004747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924323004747/doc4.xml","form_type":"4"}},{"id":2019609,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and President of R&D"}}],"security":"Common Stock","published_at":"2023-02-13T21:15:43.000Z","date":"2022-05-31","kind":"gift","acquired":false,"shares":106485,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Spouse (Jann E. Paul Revocable Trust)"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-004747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924323004747/doc4.xml","form_type":"4"}},{"id":2019608,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and President of R&D"}}],"security":"Common Stock","published_at":"2023-02-13T21:15:43.000Z","date":"2022-05-27","kind":"gift","acquired":true,"shares":106485,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Spouse (Jann E. Paul Revocable Trust)"},"balance_after":106485,"source":{"system":"sec-edgar","filing":"0000899243-23-004747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924323004747/doc4.xml","form_type":"4"}},{"id":2019607,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and President of R&D"}}],"security":"Common Stock","published_at":"2023-02-13T21:15:43.000Z","date":"2022-05-27","kind":"gift","acquired":false,"shares":106485,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Spouse (Jann E. Paul GRAT I)"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-004747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924323004747/doc4.xml","form_type":"4"}},{"id":2062111,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-01-05T21:30:07.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":2395,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2023 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2023, subject to the reporting person's continued service through such date."}],"balance_after":2395,"derivative":{"exercise_price":39.16,"expiration_date":"2033-01-04","underlying":"Common Stock","underlying_shares":2395},"source":{"system":"sec-edgar","filing":"0001562180-23-000236","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218023000236/primarydocument.xml","form_type":"4"}},{"id":2101322,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T21:15:15.000Z","date":"2022-11-28","kind":"other","acquired":true,"shares":5,"price":38.1675,"value":190.8375,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 28, 2022, the Steven Paul Revocable Trust, a family trust of which the reporting person is a trustee (the \"Revocable Trust\"), withdrew five shares of common stock from the Steven M. Paul GRAT VIII, a grantor retained annuity trust established for the benefit of the reporting person and his adult children (the \"GRAT VIII\"). In exchange for the five shares, the Revocable Trust contributed to the GRAT VIII $190.84 in cash, at a per share price equal to the average of the high and low prices of one share of the registrant's common stock on November 28, 2022. The reporting person believes that the withdrawal of the shares from the GRAT VIII constitutes a change in form of beneficial ownership of the shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by the Revocable Trust. Includes 77,533 shares previously held by the GRAT VIII and 1,000 shares previously held  by the Steven M. Paul GRAT VII which were transferred by the reporting person to Revocable Trust on November 28, 2022, in transactions exempt from reporting pursuant to Rule 16a-13 prior to the filing of this Form 4. The reporting person disclaims Section 16 beneficial ownership of the shares held in the Revocable Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose."}],"balance_after":78539,"source":{"system":"sec-edgar","filing":"0001562180-22-007940","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218022007940/primarydocument.xml","form_type":"4"}},{"id":2227313,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T20:35:27.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":9947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 16, 2023 or the day immediately prior to the 2023 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":9947,"derivative":{"exercise_price":31.36,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":9947},"source":{"system":"sec-edgar","filing":"0001562180-22-005202","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218022005202/primarydocument.xml","form_type":"4"}},{"id":2305107,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."}],"balance_after":0,"derivative":{"exercise_price":11.33,"exercise_date":"2013-06-21","expiration_date":"2022-06-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305106,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":175,"price":178.6,"value":31255.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305105,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":825,"price":177.58,"value":146503.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Sale prices ranged from $177.12 to $178.00."}],"balance_after":1175,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305104,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":526,"price":176.51,"value":92844.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Sale prices ranged from $176.04 to $176.88."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305103,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":90,"price":174.33,"value":15689.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."}],"balance_after":2526,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305102,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":642,"price":173.06,"value":111104.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Sale prices ranged from $172.83 to $173.37."}],"balance_after":2616,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305101,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":1434,"price":172.1,"value":246791.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices ranged from $171.75 to $172.73."}],"balance_after":3258,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305100,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":1235,"price":171.16,"value":211382.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $170.70 to $171.63."}],"balance_after":4692,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305099,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":4872,"price":169.71,"value":826827.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $169.32 to $170.28."}],"balance_after":5927,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305098,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":4948,"price":168.95,"value":835964.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $168.30 to $169.30."}],"balance_after":10799,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305097,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":253,"price":166.04,"value":42008.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $165.91 to $166.41."}],"balance_after":15747,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2305096,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:05:01.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":15000,"price":11.33,"value":169950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001735276-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000039/edgardoc.xml","form_type":"4"}},{"id":2387992,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option (right to buy)","published_at":"2022-02-17T22:20:03.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":146900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options shall vest on February 16, 2023, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":146900,"derivative":{"exercise_price":111.97,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":146900},"source":{"system":"sec-edgar","filing":"0001593968-22-000495","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000159396822000495/primary_01.xml","form_type":"4"}},{"id":2443341,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-01-05T21:08:42.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":1638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2022 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2022, subject to the reporting person's continued service through such date."}],"balance_after":1638,"derivative":{"exercise_price":42.21,"expiration_date":"2032-01-04","underlying":"Common Stock","underlying_shares":1638},"source":{"system":"sec-edgar","filing":"0001562180-22-000235","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218022000235/primarydocument.xml","form_type":"4"}},{"id":2514677,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-12T21:53:25.000Z","date":"2021-11-09","kind":"other","acquired":true,"shares":1,"price":43.36,"value":43.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 9, 2021, the Steven Paul Revocable Trust, a family trust of which the reporting person is a trustee (the \"Revocable Trust\"), withdrew one share of common stock from the Steven M. Paul GRAT VII, a grantor retained annuity trust established for the benefit of the reporting person and his adult children (\"GRAT VII\"). In exchange for the one share, the Revocable Trust contributed to the GRAT VII $43.36 in cash, which was the closing price of one share of the registrant's common stock on November 9, 2021. The reporting person believes that the withdrawal of the share from GRAT VII constitutes a change in form of beneficial ownership of the share, exempted by Rule 16a-13 under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by the Revocable Trust.  The reporting person disclaims Section 16 beneficial ownership of the shares held in the Revocable Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose."}],"balance_after":1,"source":{"system":"sec-edgar","filing":"0001562180-21-007019","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218021007019/primarydocument.xml","form_type":"4"}},{"id":2597536,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2021-08-18T23:43:27.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":1181,"price":106.1,"value":125304.1,"ownership":{"direct":false,"nature":"See footnote (1)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported on this Form 4 were effected by The Steven M. Paul Revocable Trust."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105.95 to $106.13, inclusive."}],"balance_after":108849,"source":{"system":"sec-edgar","filing":"0001593968-21-001992","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000159396821001992/primary_01.xml","form_type":"4"}},{"id":2597535,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2021-08-18T23:43:27.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":1183,"price":105.63,"value":124960.29,"ownership":{"direct":false,"nature":"See footnote (1)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported on this Form 4 were effected by The Steven M. Paul Revocable Trust."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105.62 to $105.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":107668,"source":{"system":"sec-edgar","filing":"0001593968-21-001992","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000159396821001992/primary_01.xml","form_type":"4"}},{"id":2630793,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2021-07-19T20:20:09.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":4032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":4032,"derivative":{"exercise_price":171.95,"exercise_date":"2022-07-15","expiration_date":"2031-07-14","underlying":"Common Stock","underlying_shares":4032},"source":{"system":"sec-edgar","filing":"0001735276-21-000066","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000066/edgardoc.xml","form_type":"4"}},{"id":2671630,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-11T20:08:03.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":76.09,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004205","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218021004205/primarydocument.xml","form_type":"4"}},{"id":2680944,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T20:34:26.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service."}],"balance_after":15000,"derivative":{"exercise_price":4.23,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-21-077079","document":"tm2118780d6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465921077079/tm2118780d6_4seq1.xml","form_type":"4"}},{"id":2835406,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Option (right to buy)","published_at":"2021-02-24T22:00:17.000Z","date":"2021-02-23","kind":"grant","acquired":true,"shares":161850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on February 23, 2022, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":161850,"derivative":{"exercise_price":131.64,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":161850},"source":{"system":"sec-edgar","filing":"0000899243-21-008030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924321008030/doc4.xml","form_type":"4"}},{"id":2905699,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T21:05:08.000Z","date":"2020-03-31","kind":"gift","acquired":true,"shares":292207,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares are fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Stock Option (Right to Buy) was gifted to The Jann E. Paul Grantor Retained Annuity Trust I.  As previously reported on June 30, 2020, on Form 4, The Jann E. Paul Grantor Retained Annuity Trust I subsequently exercised the Stock Option and sold the underlying shares."}],"balance_after":292207,"derivative":{"exercise_price":0.11,"expiration_date":"2021-03-04","underlying":"Common Stock","underlying_shares":292207},"source":{"system":"sec-edgar","filing":"0000899243-21-002178","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924321002178/doc5.xml","form_type":"5"}},{"id":2905698,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T21:05:08.000Z","date":"2020-03-31","kind":"gift","acquired":false,"shares":292207,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.11,"expiration_date":"2021-03-04","underlying":"Common Stock","underlying_shares":292207},"source":{"system":"sec-edgar","filing":"0000899243-21-002178","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924321002178/doc5.xml","form_type":"5"}},{"id":2905697,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T21:05:08.000Z","date":"2020-03-30","kind":"gift","acquired":true,"shares":292207,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares are fully vested and exercisable."}],"balance_after":292207,"derivative":{"exercise_price":0.11,"expiration_date":"2021-03-04","underlying":"Common Stock","underlying_shares":292207},"source":{"system":"sec-edgar","filing":"0000899243-21-002178","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924321002178/doc5.xml","form_type":"5"}},{"id":2905696,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T21:05:08.000Z","date":"2020-03-30","kind":"gift","acquired":false,"shares":292207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.11,"expiration_date":"2021-03-04","underlying":"Common Stock","underlying_shares":292207},"source":{"system":"sec-edgar","filing":"0000899243-21-002178","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924321002178/doc5.xml","form_type":"5"}},{"id":2934993,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-22T21:02:06.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020.  The 15,000 options exercised and sold by the reporting person were due to expire on June 9, 2021."}],"balance_after":0,"derivative":{"exercise_price":9.3,"exercise_date":"2012-06-09","expiration_date":"2021-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001735276-20-000109","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000109/edgardoc.xml","form_type":"4"}},{"id":2934992,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-22T21:02:06.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":15000,"price":140,"value":2100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020.  The 15,000 options exercised and sold by the reporting person were due to expire on June 9, 2021."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001735276-20-000109","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000109/edgardoc.xml","form_type":"4"}},{"id":2934991,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-22T21:02:06.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":15000,"price":9.3,"value":139500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020.  The 15,000 options exercised and sold by the reporting person were due to expire on June 9, 2021."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001735276-20-000109","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000109/edgardoc.xml","form_type":"4"}},{"id":3089166,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2020-07-06T20:51:41.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":4581,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4581,"derivative":{"exercise_price":148.77,"exercise_date":"2021-07-01","expiration_date":"2030-07-01","underlying":"Common Stock","underlying_shares":4581},"source":{"system":"sec-edgar","filing":"0001735276-20-000078","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000078/edgardoc.xml","form_type":"4"}},{"id":3096449,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Option (right to buy)","published_at":"2020-06-30T20:25:47.000Z","date":"2020-06-29","kind":"exercise","acquired":false,"shares":292207,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote (1)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale reported on this Form 4 were effected by the The Jann E. Paul Grantor Retained Annuity Trust I."}],"balance_after":0,"derivative":{"exercise_price":0.11,"exercise_date":"2011-03-04","expiration_date":"2021-03-04","underlying":"Common Stock","underlying_shares":292207},"source":{"system":"sec-edgar","filing":"0001593968-20-001546","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000159396820001546/primary_01.xml","form_type":"4"}},{"id":3096448,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2020-06-30T20:25:47.000Z","date":"2020-06-29","kind":"sale","acquired":false,"shares":292207,"price":103.5,"value":30243424.5,"ownership":{"direct":false,"nature":"See footnote (1)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale reported on this Form 4 were effected by the The Jann E. Paul Grantor Retained Annuity Trust I."}],"balance_after":106485,"source":{"system":"sec-edgar","filing":"0001593968-20-001546","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000159396820001546/primary_01.xml","form_type":"4"}},{"id":3096447,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2020-06-30T20:25:47.000Z","date":"2020-06-29","kind":"exercise","acquired":true,"shares":292207,"price":0.11,"value":32142.77,"ownership":{"direct":false,"nature":"See footnote (1)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale reported on this Form 4 were effected by the The Jann E. Paul Grantor Retained Annuity Trust I."}],"balance_after":398692,"source":{"system":"sec-edgar","filing":"0001593968-20-001546","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000159396820001546/primary_01.xml","form_type":"4"}},{"id":3113164,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T20:18:43.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 9, 2021 or the day immediately prior to the 2021 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":36.47,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-20-004430","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218020004430/primarydocument.xml","form_type":"4"}},{"id":3120392,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T20:16:24.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service."}],"balance_after":15000,"derivative":{"exercise_price":11.79,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-070323","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465920070323/a4.xml","form_type":"4"}},{"id":3262572,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-19T21:32:51.000Z","date":"2020-02-14","kind":"grant","acquired":false,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options shall vest on February 14, 2021, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":140000,"derivative":{"exercise_price":99.72,"expiration_date":"2030-02-14","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000899243-20-005046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924320005046/doc4.xml","form_type":"4"}},{"id":3279928,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-02-11T21:08:59.000Z","date":"2020-02-10","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019.  The 30,000 options exercised and sold by the reporting person were due to expire on September 22, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to one third of the shares on each of the first, second and third anniversaries of the grant date."}],"balance_after":0,"derivative":{"exercise_price":14.67,"expiration_date":"2020-09-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001735276-20-000010","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000010/edgardoc.xml","form_type":"4"}},{"id":3279927,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-11T21:08:59.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":30000,"price":130,"value":3900000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019.  The 30,000 options exercised and sold by the reporting person were due to expire on September 22, 2020."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001735276-20-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000010/edgardoc.xml","form_type":"4"}},{"id":3279926,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-11T21:08:59.000Z","date":"2020-02-10","kind":"exercise","acquired":true,"shares":30000,"price":14.67,"value":440100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019.  The 30,000 options exercised and sold by the reporting person were due to expire on September 22, 2020."}],"balance_after":31000,"source":{"system":"sec-edgar","filing":"0001735276-20-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000010/edgardoc.xml","form_type":"4"}},{"id":3470764,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Preferred Stock","published_at":"2019-07-02T21:18:49.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":74294,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":96485},"source":{"system":"sec-edgar","filing":"0000899243-19-018918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924319018918/doc4.xml","form_type":"4"}},{"id":3470763,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-07-02T21:18:49.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":96485,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date."}],"balance_after":106485,"source":{"system":"sec-edgar","filing":"0000899243-19-018918","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924319018918/doc4.xml","form_type":"4"}},{"id":3471566,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2019-07-02T20:05:45.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9000,"derivative":{"exercise_price":72.01,"exercise_date":"2020-07-01","expiration_date":"2029-06-30","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001735276-19-000062","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000062/edgardoc.xml","form_type":"4"}},{"id":3474570,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-02T00:26:19.000Z","date":"2019-06-28","kind":"grant","acquired":false,"shares":71121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At time of each grant, 65% of the shares underlying the grant were vested, with the remaining vesting in equal monthly installments through June 15, 2021."}],"balance_after":71121,"derivative":{"exercise_price":20.02,"expiration_date":"2019-06-28","underlying":"Common Stock","underlying_shares":71121},"source":{"system":"sec-edgar","filing":"0000899243-19-018747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924319018747/doc4.xml","form_type":"4"}},{"id":3474569,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-02T00:26:19.000Z","date":"2019-06-27","kind":"grant","acquired":false,"shares":616703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At time of each grant, 65% of the shares underlying the grant were vested, with the remaining vesting in equal monthly installments through June 15, 2021."}],"balance_after":616703,"derivative":{"exercise_price":16,"expiration_date":"2019-06-27","underlying":"Common Stock","underlying_shares":616703},"source":{"system":"sec-edgar","filing":"0000899243-19-018747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924319018747/doc4.xml","form_type":"4"}},{"id":3474568,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-07-02T00:26:19.000Z","date":"2019-06-28","kind":"purchase","acquired":true,"shares":3200,"price":23.43,"value":74976.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.35 to $23.48, inclusive.  The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-19-018747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924319018747/doc4.xml","form_type":"4"}},{"id":3474567,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-07-02T00:26:19.000Z","date":"2019-06-28","kind":"purchase","acquired":true,"shares":6800,"price":22.86,"value":155448.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $22.31 to $23.21, inclusive.  The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6800,"source":{"system":"sec-edgar","filing":"0000899243-19-018747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000089924319018747/doc4.xml","form_type":"4"}},{"id":3487761,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T23:01:06.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service."}],"balance_after":15000,"derivative":{"exercise_price":24.68,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-19-036005","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465919036005/a4.xml","form_type":"4"}},{"id":3498639,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-06T20:02:49.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 5, 2020 or the day immediately prior to the 2020 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":177.41,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-19-003395","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218019003395/primarydocument.xml","form_type":"4"}},{"id":3580908,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-22T20:22:34.000Z","date":"2019-03-21","kind":"sale","acquired":false,"shares":1967,"price":161.02,"value":316726.34,"ownership":{"direct":false,"nature":"See footnote (6)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents 30,600 shares held directly by the McGill Trust; 30,600 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 30600 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.15 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":122400,"source":{"system":"sec-edgar","filing":"0001562180-19-002013","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218019002013/primarydocument.xml","form_type":"4"}},{"id":3580907,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-22T20:22:34.000Z","date":"2019-03-21","kind":"sale","acquired":false,"shares":2919,"price":161.05,"value":470104.95,"ownership":{"direct":false,"nature":"See footnote (4)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents 30,600 shares held directly by the McGill Trust; 30,600 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.21 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":124367,"source":{"system":"sec-edgar","filing":"0001562180-19-002013","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218019002013/primarydocument.xml","form_type":"4"}},{"id":3580906,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-22T20:22:34.000Z","date":"2019-03-21","kind":"sale","acquired":false,"shares":2993,"price":161.04,"value":481992.72,"ownership":{"direct":false,"nature":"See footnote (2)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents 30,600 shares held directly by the McGill Trust; 33,519 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.20 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":127286,"source":{"system":"sec-edgar","filing":"0001562180-19-002013","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218019002013/primarydocument.xml","form_type":"4"}},{"id":3584449,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-21T00:47:15.000Z","date":"2019-03-20","kind":"sale","acquired":false,"shares":13047,"price":161.35,"value":2105133.45,"ownership":{"direct":false,"nature":"See footnote (16)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"kind","element":"transactionCoding","label":"F16","text":"Represents 33,593 shares held directly by the McGill Trust; 33,519 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"This transaction was executed in multiple trades at prices ranging from $161.00 USD to $162.46 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":130279,"source":{"system":"sec-edgar","filing":"0001562180-19-001988","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1237564/000156218019001988/primarydocument.xml","form_type":"4"}}],"next_cursor":"2019-03-21T00:47:15.000000Z,3584449"}